Right? Where do they find all these blind doctors?
On Thu, Apr 1, 2021 at 12:37 PM Mary Lou Carey <[email protected]> wrote: > Maybe they should open their eyes instead of doing a double-blind study! > LOL! > > MARY LOU CAREY > BackUP Telecom Consulting > Office: 615-791-9969 > Cell: 615-796-1111 > > On 2021-04-01 02:27 PM, Hiers, David wrote: > > No AI here... This is classic, small-batch, hand-crafted, free-range, > > organic, gluten-free content. > > > > > > David > > > > > > -----Original Message----- > > From: VoiceOps <[email protected]> On Behalf Of Alex > > Balashov > > Sent: Thursday, April 1, 2021 12:18 PM > > To: Brandon Svec <[email protected]> > > Cc: [email protected] > > Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ > > > > Let me make sure I understand your question correctly: it is your > > belief or conjecture that this press release was automatically > > generated by a machine learning system? > > > > — > > Sent from mobile, with due apologies for brevity and errors. > > > >> On Apr 1, 2021, at 3:10 PM, Brandon Svec <[email protected]> > >> wrote: > >> > >> GPT-3? Happy April Fools Day. > >> > >> Brandon > >> > >>> On Mar 31, 2021, at 9:47 PM, Alex Balashov > >>> <[email protected]> wrote: > >>> > >>> For immediate release: > >>> > >>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership > >>> with Posner | Palner Pharmaceuticals, are pleased to announce the > >>> eagerly anticipated start of Phase III clinical trials of Kamailio > >>> DMQ module replication. > >>> > >>> In this stage of the investigation of the promising replication > >>> scheme, which was developed in record time, DMQ will be tested in a > >>> rigourous, double-blind, controlled CI/CD process for large-scale > >>> efficacy and continually monitored for safety in shorter and longer > >>> terms. > >>> > >>> The now-concluded second phase established basic safety and Phase 2b > >>> entailed a dose-finding study for the optimal number of batched > >>> `dmq_usrloc` contacts per kilogram of cloud computing resource. > >>> > >>> The main cohort of the main sequence of the Phase III trial will > >>> enroll 380 randomly selected, statistically representative Floridian > >>> SIP registrars and > >>> 5700 SIP dialogs, also in the state of Florida. When asked about the > >>> disparity in the number of registrars versus dialogs, Alex Balashov > >>> of Evariste said, "It is reflective of the small number of SIP > >>> registrars in Florida; not to be indelicate, but consider the median > >>> age of the population." > >>> > >>> As previously remarked upon in proceedings of the World SIP > >>> Organisation (WSO), the choice of Florida as a venue attracted some > >>> questions. We asked Fred Posner of Posner | Palner about the clinical > >>> background informing this choice of replication study cohort: > >>> > >>> "Florida is a good place to find eventual consistency failures; the > >>> open climate and reluctance to accept traditional data integrity > >>> science would have sealed the deal, but when people started to drink > >>> bleach here, I saw an opportunity." > >>> > >>> Evariste and Posner | Palner are aiming for a US Food & Drug > >>> Administration EUA (Emergency Use Authorisation) for DMQ replication > >>> as a prophylactic data redundancy and failover measure to ward off > >>> the development of moderate to severe viral Sonus Haemorrhagic Fever > >>> symptoms. > >>> > >>> Phase II studies have painted a promising a picture of the DMQ > >>> architecture's ability to reduce moderate to severe symptoms and > >>> associated 28-day mortality by more than 90%, albeit over a small > >>> sample size and in enterprise patients with known pre-existing > >>> comorbidities such as Session Border Controller and BroadSoft > >>> Multi-System Inflammatory Syndrome. Phase III trials seek to bolster > >>> quantums of broader efficacy, including efficacy for localised > >>> outbreaks of small to medium business softswitch. > >>> > >>> Of the control group, Balashov said, "They will receive a standard > >>> pipe-to-/dev/null placebo protocol, but with identical '200 OK' > >>> confirmation messages. We proudly developed this approach in early > >>> 2020 in consultation with the highest levels of the Trump > >>> presidential administration; it is called TENP, or 'The Emperor's New > >>> Potion.' It is a successor to that administration's previous approved > >>> placebo protocol, SHTI - Small Hands, Tremendous Initiatives." > >>> > >>> Despite speculative autism and packet fragmentation claims by Florida > >>> Governor Ron DeSantis, Balashov was quick to provide reassurance > >>> about side effects from DMQ in the Phase III trial. > >>> > >>> "The incidence of severe allergies to plain-text UDP was within > >>> standard deviation over the mean for all insecure replication, and > >>> there's support for other transports on the way. Anyway, we have a > >>> robust adverse effects reporting system in our issue tracker and > >>> solid surveillance. Don't let partisan politics dissuade you from > >>> allowing request lines with the KDMQ method." > >>> > >>> Other industry sources have reported that DMQ is not the only > >>> replication investigation undertaken by Evariste and Posner | Palner, > >>> although it is the only prophylactic suitable for the early infection > >>> development and inflammatory phases of a broad class of SBC-complex > >>> syndromes typically afflicting service providers. A recent IETF > >>> preprint by the same authors has shown high-quality preliminary data > >>> suggesting statistically significant improvement in morbidity > >>> outcomes from Perimeta and Nokia via a later-stage therapeutic > >>> intervention with a monoclonal, monorepo Github cocktail administered > >>> intravenously. > >>> > >>> > >>> -- > >>> Alex Balashov | Principal | Evariste Systems LLC > >>> > >>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) > >>> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ > >>> _______________________________________________ > >>> VoiceOps mailing list > >>> [email protected] > >>> https://puck.nether.net/mailman/listinfo/voiceops > > _______________________________________________ > > VoiceOps mailing list > > [email protected] > > https://puck.nether.net/mailman/listinfo/voiceops > > > > ---------------------------------------------------------------------- > > This message and any attachments are intended only for the use of the > > addressee and may contain information that is privileged and > > confidential. If the reader of the message is not the intended > > recipient or an authorized representative of the intended recipient, > > you are hereby notified that any dissemination of this communication > > is strictly prohibited. If you have received this communication in > > error, notify the sender immediately by return email and delete the > > message and any attachments from your system. > > _______________________________________________ > > VoiceOps mailing list > > [email protected] > > https://puck.nether.net/mailman/listinfo/voiceops > _______________________________________________ > VoiceOps mailing list > [email protected] > https://puck.nether.net/mailman/listinfo/voiceops >
_______________________________________________ VoiceOps mailing list [email protected] https://puck.nether.net/mailman/listinfo/voiceops
